Wagener, Katharina
Beckhaus, Julia
Boekhoff, Svenja
Friedrich, Carsten
Müller, Hermann L. http://orcid.org/0000-0003-4929-9966
Funding for this research was provided by:
Deutsche Kinderkrebsstiftung (DKS2014.13)
Article History
Received: 25 April 2023
Accepted: 13 May 2023
First Online: 4 July 2023
Change Date: 29 August 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s11060-023-04424-1
Declarations
:
: H.L.M. has received reimbursement of participation fees for scientific meetings and continuing medical education events from the following companies: Ferring, Lilly, Pfizer, Sandoz/Hexal, Novo Nordisk, IPSEN, and Merck Serono. He has received reimbursement of travel expenses from IPSEN and lecture honoraria from Pfizer. The other authors declare that they have no conflict of interest.
: All procedures performed in our study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The studies KRANIOPHARYNGEOM 2000 (Clinical trial registration number: NCT00258453) and KRANIOPHARYNGEOM 2007 (Clinical trial registration number: NCT01272622) were approved by the local standing-committee on ethical practice of the Medizinische Fakultät, Julius-Maximilians-Universität Würzburg, Germany (140/99; 94/06, respectively). Approval of the KRANIOPHARYNGEOM Registry 2019 and our meningioma study was granted by the Ethics Committee of Medical Faculty of the Carl von Ossietzky University of Oldenburg, Oldenburg, Germany (No: 2019-046, Date. 12/06/2019; No: 2021 − 166, Date 16/12/2021).
: Written parental and/or patient consent was obtained from all individual participants and their parents included in the study.
: Written consent for publication of results based on analyses of anonymized data was obtained from individual participants and/or legal guardians.